Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: GlobeNewswire
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for introduction of radioactive material and continued positive momentum toward initiating Alpha DaRT treatment manufacturing in 2026 - JERUSALEM, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® announced today that it has secured a radioactive material license from the State of New Hampshire Bureau of Public Health Protection, Radiological Health Section, following completion of the first phase of construction of its commercial-scale manufacturing facility in Hudson, New Hampshire. In October 2023, the Company entered into a long-term lease agreement for a standalone building of over 14,000 rentable square feet in Hudso
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI SymposiumGlobeNewswire
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate CancerGlobeNewswire
- Alpha Tau to Participate in December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Alpha Tau to Participate in December Investor ConferencesGlobeNewswire
- Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
DRTS
Earnings
- 11/20/25 - Beat
DRTS
Sec Filings
- 12/4/25 - Form 6-K
- 12/2/25 - Form 6-K
- 12/1/25 - Form 144
- DRTS's page on the SEC website